SCHEMBL352724

SCHEMBL352724

Cc1cccc(Nc2nc3ncnc-3c(NC3C4CCC(C4)C3C(N)=O)[nH]2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 14/20 0.37
KCNH2 Q12809 11/20 0.37
AURKB Q96GD4 11/20 0.37
MAPK1 P28482 8/20 0.37
MAPK3 P27361 7/20 0.37
KDR P35968 4/20 0.37
IRAK4 Q9NWZ3 2/20 0.36
MAP3K7 O43318 1/20 0.36
ABL1 P00519 2/20 0.36
EGFR P00533 1/20 0.36
ABL2 P42684 1/20 0.36
GP6 Q9HCN6 1/20 0.36
CDC7 O00311 1/20 0.36
PLK4 O00444 1/20 0.36
CHEK1 O14757 1/20 0.36
PDPK1 O15530 1/20 0.36
DAPK3 O43293 1/20 0.36
DYRK3 O43781 1/20 0.36
JAK2 O60674 1/20 0.36
ROCK2 O75116 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4763191 0.88 IRAK4 (0.48) IRAK4MAP3K7
SCHEMBL352309 0.83 SYK (0.42) SYKAURKBKDREGFRPRKCI
SCHEMBL350535 0.80 SYK (0.41) SYKKCNH2AURKBMAPK1KDR
SCHEMBL1306299 0.80 AURKB (0.40) SYKKCNH2AURKBMAPK1MAPK3
SCHEMBL351077 0.80 SYK (0.42) SYKAURKBKDRJAK2ALK
SCHEMBL351556 0.79 ADORA2A (0.37) MAPK1IRAK4ABL1EGFRABL2
SCHEMBL4790642 0.78 IRAK4 (0.45) IRAK4MAP3K7
SCHEMBL1306083 0.78 IRAK4 (0.49) IRAK4MAP3K7
SCHEMBL1307874 0.78 IRAK4 (0.49) IRAK4MAP3K7
SCHEMBL352460 0.78 IRAK4 (0.49) IRAK4MAP3K7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960372-B1 KINASE INHIBITORS AND THEIR USES RIGEL PHARMACEUTICALS INC (US) 2015-12-09 EP claimed
EP-1960372-A1 KINASE INHIBITORS AND THEIR USES Rigel Pharmaceuticals, Inc. (US) 2008-08-27 EP claimed
WO-2007070872-A1 KINASE INHIBITORS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2007-06-21 WO claimed
US-9834568-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2017-12-05 US disclosed
US-20160024116-A1 Kinase Inhibitors And Their Uses MIDCAP FINANCIAL TRUST 2016-01-28 US disclosed
US-9096542-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2015-08-04 US disclosed
US-20120015937-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015937-A1 Kinase Inhibitors And Their Uses BTK, SYK, LYN SYK 2/4885KCNH2 4598/4885AURKB 233/4885
US-20160024116-A1 Kinase Inhibitors And Their Uses BTK, SYK, LYN SYK 2/4885KCNH2 4598/4885AURKB 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.